Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 19, 2013
First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System Boston Scientific Corporation (NYSE: BSX) has launched a...
-
Jul 19, 2013Boston Scientific Launches Trial To Evaluate Neurostimulation For Treatment Of Chronic Migraine [EN]First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System
Boston Scientific Corporation (NYSE: BSX) has launched a clinical trial to determine whether occipital nerve stimulation (ONS) using the Precision™ System can safely and effectively treat...
-
Jun 28, 2013Transaction to Accelerate Boston Scientific Expansion in Growing Electrophysiology Market
In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific Corporation (NYSE:BSX) has entered into a...
-
Jun 26, 2013
The first patient implant of the Boston Scientific Corporation (NYSE: BSX) VITALIO™ pacemaker was performed at ZGT Hengelo in Hengelo, the Netherlands. In addition to a comprehensive suite of...
-
Jun 25, 2013
Boston Scientific Corporation (NYSE: BSX) is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and support insight into the patient?s...
-
Jun 24, 2013Outcomes Follow Recent NICE Guidance Supporting Safety and Effectiveness of Subcutaneous Implantable Defibrillators
The Boston Scientific Corporation (NYSE:BSX) S-ICD® (subcutaneous implantable defibrillator) System showed a significant reduction in major lead-related complications when compared with both...
-
May 28, 2013
Boston Scientific Corporation (NYSE: BSX) presenta i risultati positivi di due studi clinici riguardanti nuove ed innovative tecnologie di stent medicati (DES), che rappresentano opzioni...
-
May 28, 2013Nuovi dati clinici sono stati presentati durante l'EuroPCR nel corso di una Late Breaking Clinical Trial Session e hanno dimostrato risultati positivi in termini di minino rigurgito paravalvolare, a 30 giorni, nei primi 60 pazienti trattati con la valvola Lotus™
Boston Scientific Corporation (NYSE: BSX) presenta i risultati positivi di un'analisi pre-specificata dei primi 60 pazienti arruolati nello studio REPRISE II, che valuta la performance e la...
-
May 27, 2013In einer Late-Breaking-Session des EuroPCR Kongresses wurden neue Daten zum erfolgreichen Einsatz derLotus™-Aortenklappe für die ersten 60 Patienten der REPRISE II Studie vorgestellt. Nach 30 Tagen traten kaum Fälle einer paravalvulären Aorteninsuffizienz auf.
Die Boston Scientific Corporation (NYSE: Adaptive Seal™" zur Minimierung paravalvulärer Lecks. Letztere sind ein Mortalitätsprädiktor. Die Klappe ist repositionierbar und bergbar (vor dem...
-
May 27, 2013
Die Boston Scientific Corporation (NYSE: BSX) hat positive Ergebnisse zweier Studien zur innovativen Technologie medikamentenfreisetzender Stents (DES), die sich als richtungsweisende Behandlungen...
-
May 27, 2013Presentados hoy en EuroPCR los datos provisionales del programa clínico REDUCE-HTN
Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy los datos provisionales del programa clínico REDUCE-HTN, que demuestran una reducción significativa y duradera de la tensión arterial...
-
May 27, 2013Interimdaten aus dem klinischen Programm REDUCE-HTN wurden heute auf dem EuroPCR präsentiert
Boston Scientific Corporation (NYSE: BSX) hat heute Interimdaten aus dem klinischen Programm REDUCE-HTN präsentiert, die eine signifikante und nachhaltige Reduktion des Blutdrucks bei Patienten...
-
May 22, 2013
Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for...
-
May 22, 2013
Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial evaluating the performance and safety of...
-
May 22, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair® Bronchial Thermoplasty (BT)...
-
May 21, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair® Bronchial Thermoplasty (BT)...
-
May 21, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair® Bronchial Thermoplasty (BT)...
-
May 21, 2013
Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial presented today demonstrated that the Boston Scientific Corporation (NYSE: BSX) Alair® Bronchial Thermoplasty (BT)...
-
May 17, 2013
"We are pleased to present a particularly rich and diversified set of data this year at EuroPCR," said Keith Dawkins, M.D., global chief medical officer, Boston Scientific. "The primary endpoint...
-
May 17, 2013
Boston Scientific Corporation (NYSE:BSX) is scheduled to participate at the annual EuroPCR Scientific Program May 21-24 in Paris. "We are pleased to present a particularly rich and diversified set...
-
May 17, 2013
Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial Results of REPRISE I Study Suggest Device Minimizes Aortic Regurgitation Boston Scientific Corporation...
-
May 16, 2013Dati preliminari del programma clinico REDUCE-HTN sono stati presentati oggi all'EuroPCR
Nel corso di EuroPCR, uno dei più importanti congressi internazionali di cardiologia interventistica che si è svolto di recente a Parigi, BOSTON SCIENTIFIC ha presentato i dati preliminari del...
-
May 10, 2013Company Offers Mapping System with IntellaMap Orion™ Mapping Catheter in Effort to Significantly Enhance Physician Treatment Options
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the Rhythmia™ Mapping System, a next-generation 3D mapping and navigation solution for use in cardiac catheter...
-
May 10, 2013Industry-Leading Battery Life Reduces the Frequency of Replacement Surgery
New data from 100,438 patients with Boston Scientific Corporation (NYSE:BSX) implantable cardiac defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) followed in the...
-
May 10, 2013Separate Study Demonstrates PROMUS Element Stent has Significantly Less Vessel Straightening than the Xience V® Stent
Boston Scientific Corporation (NYSE: BSX) reported clinical endpoint data from the PLATINUM workhorse clinical trial comparing the safety and effectiveness of the PROMUS Element™...